Tuscaloosa Research & Education Advancement Corporation
15
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
26.7%
4 terminated/withdrawn out of 15 trials
69.2%
-17.3% vs industry average
47%
7 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Minds Navigating the Diagnosis of Mild Cognitive Impairment
Role: lead
Alabama Veterans Rural Health Initiative
Role: lead
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans
Role: lead
Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade
Role: lead
Divalproex vs. Lamotrigine for Bipolar Disorder
Role: lead
Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia
Role: lead
Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder
Role: lead
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
Role: lead
Impact of Supported Employment Versus Standard Vocational Rehabilitation in Veterans With Post-traumatic Stress Disorder
Role: lead
Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
Role: lead
Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)
Role: lead
Carbamazepine Extended-Release for the Treatment of Bipolar Depression
Role: lead
Characterization of Recently Deployed Veterans
Role: lead
Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder
Role: lead
Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years
Role: lead
All 15 trials loaded